Showing results (41-50 of 154) with videos related to
Sort By:
Pageof 16
International Journal of Molecular Sciences|June 27, 2024
Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic LeukemiaWael Gamal, Melanie Mediavilla-Varela, Angimar Uriepero-Palma, et al.Oncotargets and Therapy|August 30, 2016
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedJavier Pinilla-Ibarz, Kendra L Sweet, Gabriela M Corrales-Yepez, et al.Cancer|July 12, 2008
Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemiaMohamed A Kharfan-Dabaja, Julio C Chavez, Khadija A Khorfan, et al.Leukemia Research Reports|September 6, 2019
T315I-mutated myeloid sarcomaYumeng Zhang, David M Swoboda, Aditya Grover, et al.Expert Review of Hematology|February 9, 2026
Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphomaJavier Pinilla-Ibarz, Mei Xue, Elizabeth Wu, et al.American Journal of Hematology|March 25, 2015
WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptidesJason Brayer, Jeffrey E Lancet, John Powers, et al.Leukemia Research|January 3, 2012
Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CMLRajesh R Nair, Joel H Tolentino, Raul F Argilagos, et al.Immunology Letters|March 30, 2010
Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3Jason Brayer, Fengdong Cheng, Hongwei Wang, et al.Molecular Cancer Therapeutics|October 15, 2008
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistanceNadine N Bewry, Rajesh R Nair, Michael F Emmons, et al.Current Pharmaceutical Design|January 30, 2010
Circumventing immune tolerance through epigenetic modificationJason A Dubovsky, Alejandro Villagra, John J Powers, et al.Pageof 16